Predict your next investment

Venture Capital
affentrangerassociates.com

See what CB Insights has to offer

Investments

18

Portfolio Exits

5

Funds

2

About Affentranger Associates

Incorporated in 2002, Affentranger Associates is a business platform focused on the theme of value creation with its core competency in hands-on management. As principal investor, Affentranger Associates has the ambition to achieve sustainable long term returns through a symbiosis of capital and labour investments into companies in a transition. As strategic advisor, Affentranger Associates creates value for its clients through independent unbiased strategic advice and flawless execution of transactions.

Affentranger Associates Headquarter Location

Rue du Rhône 100

1204,

Switzerland

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Affentranger Associates

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Affentranger Associates in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Latest Affentranger Associates News

Corporate finance activities of Affentranger Associates SA sold to Capitalmind AG

Mar 25, 2021

The corporate finance assets and activities of Affentranger Associates SA (“AASA”) have been sold to Markus Decker through his newly founded Zürich based Corporate Finance boutique Capitalmind AG. The AASA portfolio includes ventures such as Selfrag and Dartfish. Markus Decker, since 2011 Managing Partner of Affentranger Associates SA, will lead the continuation and further development of the AASA corporate finance business. “I’m very pleased to be able to pass on our corporate finance activities to Markus. He will continue the further successful development of a unique niche player in the Swiss corporate finance market” says Anton Affentranger majority shareholder of AASA. “We will continue to develop the corporate finance business with the same full commitment to hard work and to the highest professional and ethical standards as in the past” stresses Markus Decker. AASA has been merged with Corporate Investment Management Affentranger Holding SA (“CIMA SA”). The merged entity will continue to develop its principal investment activities. “We are excited to continue focussed on the management of our current and future investment portfolio” concludes Anton Affentranger. Capitalmind AG will take over all current intellectual, business and human resources of AASA and will become the Swiss arm of Capitalmind , one of Europe’s largest independent corporate finance firms with more than 65 professionals in France, Germany, Benelux and Scandinavia. The parties have agreed to keep the value of the announced transaction confidential. (Press release / SK)

Affentranger Associates Investments

18 Investments

Affentranger Associates has made 18 investments. Their latest investment was in InflaRx as part of their Series B on July 7, 2014.

CBI Logo

Affentranger Associates Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/17/2014

Series B

InflaRx

No

bm-t beteiligungsmanagement thuringen

1

3/15/2011

Series B

selFrag

$9.8M

No

Credit Suisse Entrepreneur Capital, Helvetica Capital, and Undisclosed Investors

1

11/17/2010

Unattributed VC - IV

SomaLogic

$15M

No

LODH Private Equity Partners, Mitsui & Co. Global Investment, NEC, NewWest Capital Partners, Otsuka Holdings, ProQuest Investments, Quest Diagnostics, Skye Investment Advisors, and Sumitomo Bakelite

5/7/2010

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

10

12/14/2009

Debt

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/17/2014

3/15/2011

11/17/2010

5/7/2010

12/14/2009

Round

Series B

Series B

Unattributed VC - IV

Unattributed VC

Debt

Company

InflaRx

selFrag

SomaLogic

Subscribe to see more

Subscribe to see more

Amount

$9.8M

$15M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

bm-t beteiligungsmanagement thuringen

Credit Suisse Entrepreneur Capital, Helvetica Capital, and Undisclosed Investors

LODH Private Equity Partners, Mitsui & Co. Global Investment, NEC, NewWest Capital Partners, Otsuka Holdings, ProQuest Investments, Quest Diagnostics, Skye Investment Advisors, and Sumitomo Bakelite

Sources

1

1

10

10

Affentranger Associates Portfolio Exits

5 Portfolio Exits

Affentranger Associates has 5 portfolio exits. Their latest portfolio exit was SomaLogic on March 29, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/29/2021

Acq - Pending

$991

3

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

3/29/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Exit

Acq - Pending

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

10

10

10

10

Affentranger Associates Fund History

2 Fund Histories

Affentranger Associates has 2 funds, including Immunology Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

Immunology Fund

Buyouts & Acquisitions

1

Ultreia Capital Ltd. Fund

Subscribe to see more

$99M

10

Closing Date

Fund

Immunology Fund

Ultreia Capital Ltd. Fund

Fund Type

Buyouts & Acquisitions

Subscribe to see more

Status

Amount

$99M

Sources

1

10

Affentranger Associates Team

5 Team Members

Affentranger Associates has 5 team members, including current Managing Partner, Lukas Andre.

Name

Work History

Title

Status

Lukas Andre

Managing Partner

Current

Markus Decker

Managing Partner

Current

Anton Affentranger

Senior Partner

Current

Gustav Christensen

Phylos, and Commonwealth Bioventures

Chief Executive Officer

Former

Barbara Zink

Managing Director

Former

Name

Lukas Andre

Markus Decker

Anton Affentranger

Gustav Christensen

Barbara Zink

Work History

Phylos, and Commonwealth Bioventures

Title

Managing Partner

Managing Partner

Senior Partner

Chief Executive Officer

Managing Director

Status

Current

Current

Current

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.